Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 9
Submit an article Journal homepage
321
Views
4
CrossRef citations to date
0
Altmetric
Letters to the Editor

HSP90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics

Tzung-Huei LaiDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
Shaneice MitchellDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
Pei-Jung WuDivision of Neuro-oncology, Department of Neurosurgery, The Ohio State University, Columbus, OH, USA; View further author information
,
Shelley OrwickDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
Chaomei LiuDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Janani RavikrishnanDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
Jennifer WoyachDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
Alice MimsDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
William PlunkettDepartment of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Vinay K. PuduvalliDivision of Neuro-oncology, Department of Neurosurgery, The Ohio State University, Columbus, OH, USA; View further author information
,
John C. ByrdDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; View further author information
,
Rosa LapalombellaDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; View further author information
&
Deepa SampathDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; Correspondence[email protected]
View further author information
 show all
Pages 2308-2311 | Received 22 Sep 2018, Accepted 09 Jan 2019, Published online: 18 Feb 2019

References

  • Stone RM, Mandrekar SJ, Sanford BL. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454–464.
  • Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011;364:1027–1036.
  • Wu D, Duan C, Chen L, et al. Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis. Scientif Rep. 2017;7:9509.
  • Burnett AK, Russell N, Hills RK, et al. A randomised comparison of the novel nucleoside analogue sapacitabine with low-dose cytarabine in older patients with acute myeloid leukaemia. Leukemia. 2015;29:1312–1319.
  • Liu X, Wang Y, Benaissa S, et al. Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC. Blood. 2010;116:1737–1746.
  • Strom SS, Estey E, Outschoorn UM, et al. Acute myeloid leukemia outcome: role of nucleotide excision repair polymorphisms in intermediate risk patients. Leuk Lymphoma. 2010;51:598–605.
  • Dote H, Burgan WE, Camphausen K, et al. Inhibition of Hsp90 compromises the DNA damage response to radiation. Cancer Res. 2006;66:9211–9220.
  • Ceccaldi R, Rondinelli B, D'Andrea AD. Repair pathway choices and consequences at the double-strand break. Trends Cell Biol. 2016;26:52–64.
  • Sharma A, Singh K, Almasan A. Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol. 2012;920:613–626.
  • Gachechiladze M, Skarda J, Soltermann A, et al. RAD51 as a potential surrogate marker for DNA repair capacity in solid malignancies. Int J Cancer. 2017;141:1286–1294.
  • David L, Fernandez-Vidal A, Bertoli S, et al. CHK1 as a therapeutic target to bypass chemoresistance in AML. Sci Signal. 2016;9:ra90.
  • Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res. 2012;18:64–76.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.